We are live on !
Find out more
Cellectis
CLLS
CLLS
About: Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Employees: 229
News
Positive
Neutral
Negative
Sentiment
3-Months
Positive
3.1%
Neutral
87.5%
Negative
9.4%
Price charts implemented using Lightweight Charts™